# Long-Term Nonprogressive Interstitial Lung Disease in Anti-PL-12- and Anti-Ro52-Positive Antisynthetase Syndrome Without Immunosuppressive Therapy

## TL;DR

A patient with a specific lung disease and antibodies remained stable for years without treatment, showing that not all high-risk cases progress.

## Contribution

Highlights the variability in disease progression for anti-PL-12-associated conditions, even with high-risk antibody profiles.

## Key findings

- A patient with anti-PL-12 and anti-Ro52 antibodies had stable lung disease for years.
- The case shows some individuals may not require immunosuppressive therapy despite high-risk antibody profiles.

## Abstract

Antisynthetase syndrome (ASS) is an autoimmune condition associated with aminoacyl-tRNA synthetases (ARS) antibodies and often presents with interstitial lung disease (ILD). We describe a patient with ILD and positive anti-PL-12 and anti-Ro52 antibodies. Although these antibodies are generally linked with more active or progressive lung disease, this patient remained clinically stable for several years without immunosuppressive therapy. This case illustrates the broad variability in the clinical expression and course of anti-PL-12-associated disease and shows that some individuals may experience long periods of remission despite serologic profiles often considered high-risk.